Recombinant SARS-CoV-2 fusion protein vaccine (V-01)

BIOLOGICAL2 trials

Sponsors

Livzon Pharmaceutical Group Inc.

Conditions

COVID-19 Pandemic

Phase 3

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

CompletedNCT05096832

Livzon Pharmaceutical Group Inc.COVID-19 Pandemic

Start: 2021-11-03End: 2023-04-14Updated: 2023-04-25

Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Phase III

Livzon Pharmaceutical Group Inc.COVID-19 Pandemic

Start: 2021-08-25End: 2023-06-14Target: 22500Updated: 2023-04-25

Related Papers

Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial

Emerging Microbes & Infections2022-06-1044 citations